Pancreatic Cancer Research

ResearcherKyoto Prefectural University of MedicineActive in the last 2 years

Daisuke Ichikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0093-2206; OpenAlex author ID A5026517739. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. To Evaluate Whether Pretreatment CA19-9 and DUPAN-2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Ca… Last author DOI 10.1002/ags3.70140↗
  2. The post-neoadjuvant absolute lymphocyte count reflects the pathological response and local tumor control in pancreatic cancer. Last author DOI 10.1007/s00595-026-03412-y↗
  3. Prognostic Significance of Extrapancreatic Invasion in Pancreatic Cancer: Excellent Outcomes in Patients With Disease Confined Within the Pancreas. Last author DOI 10.21873/anticanres.18011↗
  4. Prognostic Significance of Splenic Vein Invasion for Pancreatic Cancer Patients With Pancreatectomy: A Retrospective Study. Last author DOI 10.21873/anticanres.17465↗
  5. Re-consideration of Lymph Node Metastasis in Pancreatic Cancer Patients Following Radical Resection: A Retrospective Study. Last author DOI 10.21873/anticanres.17020↗
  6. Predictors of the therapeutic effect of Nab-paclitaxel plus gemcitabine therapy for patients with recurrent pancreatic cancer after pancreatectomy Last author DOI 10.21203/rs.3.rs-3201226/v1↗
  7. Cytoglobin as a Prognostic Factor for Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis of 75 Patients. Last author DOI 10.1097/mpa.0000000000001871↗
  8. Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression. Last author DOI 10.1245/s10434-021-10250-4↗
  9. High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. Co-author DOI 10.7150/jca.63244↗
  10. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001371↗
  11. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Last author DOI 10.21873/anticanres.13019↗
  12. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1038/s41598-017-04191-w↗
  13. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Co-author DOI 10.1038/s41598-017-06137-8↗
  14. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. Co-author DOI 10.3748/wjg.v22.i25.5627↗
  15. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Co-author DOI 10.1038/bjc.2015.366↗
  16. Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Co-author DOI 10.1016/j.pan.2014.09.006↗
  17. The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Co-author PMID 24778048↗
  18. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2012.546↗
  19. Enhancement of the cytocidal effects of hypotonic solution using a chloride channel blocker in pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2012.08.003↗
  20. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2011.453↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromichi Kawaida · 11 shared papers, 2018–2026 · strength 1.86
  2. Wataru Izumo · 5 shared papers, 2024–2026 · strength 1.23
  3. Ryo Saito · 3 shared papers, 2026 · strength 0.83
  4. Ryo Saito · 5 shared papers, 2021–2025 · strength 0.76
  5. Hiroshi Kono · 5 shared papers, 2018–2023 · strength 0.52
  6. Eigo Otsuji · 9 shared papers, 2011–2017 · strength 0.37
  7. Atsushi Shiozaki · 8 shared papers, 2011–2017 · strength 0.30
  8. Shinichi Takano · 3 shared papers, 2018–2023 · strength 0.28
  9. Ryo Morimura · 7 shared papers, 2011–2017 · strength 0.27
  10. Satoshi Kawakami · 2 shared papers, 2019–2023 · strength 0.22
  11. Nobuyuki Enomoto · 2 shared papers, 2019–2023 · strength 0.22
  12. Hideki Fujii · 2 shared papers, 2018–2023 · strength 0.20
  13. Mahito Miyamae · 3 shared papers, 2015–2017 · strength 0.15
  14. Taisuke Imamura · 3 shared papers, 2015–2017 · strength 0.15
  15. Tsutomu Kawaguchi · 3 shared papers, 2013–2016 · strength 0.12
  16. Sho Kiritani · 1 shared paper, 2021 · strength 0.12
  17. Genki Watanabe · 1 shared paper, 2021 · strength 0.12
  18. Tomohiko Iwano · 1 shared paper, 2021 · strength 0.12
  19. Sén Takeda · 1 shared paper, 2021 · strength 0.12
  20. Hidekazu Hiramoto · 1 shared paper, 2017 · strength 0.08
  21. Johji Inazawa · 1 shared paper, 2017 · strength 0.08
  22. Makoto Kadokura · 1 shared paper, 2019 · strength 0.08
  23. Yusuke Yamamoto · 2 shared papers, 2014 · strength 0.07
  24. Shintaro Ichikawa · 1 shared paper, 2018 · strength 0.06
  25. Yoshito Nako · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.